Table 1 AHP, pacemaker frequency and its precision, as well as D2-AR responses in SN DA neurons from WT and Cav1.3 KO mice.
control conditions | control conditions | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
juvenile WT | n | juvenile CaV1.3 KO | n | U | p | adult WT | n | adult CaV1.3 KO | n | U | p | |
afterhyperpolarisation [mV] (whole-cell) | −59.27 ± 0.6 | 47 | −55.25 ± 0.9 | 40 | 560 | 0.001 | −56.52 ± 0.8 | 46 | −59.75 ± 1.1 | 22 | 327 | 0.02 |
pacemaker frequency [Hz] (five minutes, perforated patch) | 2.67 ± 0.3 | 7 | 2.07 ± 0.3 | 9 | 15.5 | 0.1 | 3.18 ± 0.2 | 9 | 3.34 ± 0.3 | 13 | 55 | 0.8 |
CV ISI [%] (perforated patch) | 7.71 ± 0.9 | 7 | 16.77 ± 4 | 9 | 15 | 0.09 | 7.13 ± 2 | 5 | 11.36 ± 2.3 | 6 | 6 | 0.1 |
CV2 [%] (perforated patch) | 3.87 ± 0.4 | 7 | 7.71 ± 2 | 9 | 19 | 0.2 | 2.92 ± 0.7 | 5 | 5.35 ± 1 | 6 | 4 | 0.05 |
activity at min. 15 of dopamine [%] (perforated patch) | 43.11 ± 11.9 | 5 | 11.55 ± 7.6 | 9 | 39 | 0.02 | 12.13 ± 6.1 | 7 | 12.59 ± 5.4 | 12 | 49 | 1 |
in 300 nM isradipine | in 300 nM isradipine | |||||||||||
juvenile WT | n | juvenile CaV1.3 KO | n | U | p | *adult WT | n | adult CaV1.3 KO | n | U | p | |
afterhyperpolarisation [mV] (whole-cell) | −56.94 ± 1.2 | 14 | −56.44 ± 1.3 | 14 | 88 | 0.7 | −59.81 ± 1.3 | 12 | −59.3 ± 1.5 | 11 | 53 | 0.4 |
pacemaker frequency [Hz] (five minutes, perforated patch) | 2.57 ± 0.04 | 7 | 1.96 ± 0.1 | 9 | 8 | 0.01 | 3.19 ± 0.3 | 9 | ||||
CV ISI [%] (perforated patch) | 8.85 ± 1.5 | 8 | 15.53 ± 3.5 | 8 | 17 | 0.1 | 9.9 ± 1.2 | 8 | ||||
CV2 [%] (perforated patch) | 3.73 ± 0.8 | 8 | 8.88 ± 2.6 | 8 | 12 | 0.04 | 5.7 ± 0.7 | 8 | ||||
activity at min. 15 of dopamine [%] (perforated patch) | 34.29 ± 9.9 | 7 | 5.39 ± 2.5 | 9 | 9 | 0.01 | 1.5 ± 3.2 | 13 | ||||
in 10 μM Z941 | in 10 μM Z941 | |||||||||||
juvenile WT | n | juvenile CaV1.3 KO | n | U | p | adult WT | n | adult CaV1.3 KO | n | U | p | |
afterhyperpolarisation [mV] (whole-cell) | −59.06 ± 0.8 | 17 | −58.4 ± 1.6 | 14 | 118 | 1 | ||||||
pacemaker frequency [Hz] (five minutes, perforated patch) | 2.19 ± 0.3 | 10 | 2.41 ± 0.3 | 8 | 31 | 0.5 | 2.4 ± 0.1 | 13 | 1.4 ± 0.1 | 10 | 6 | <0.0001 |
CV ISI [%] (perforated patch) | 12.44 ± 1.3 | 7 | 12.25 ± 1.4 | 7 | 20 | 0.6 | 7.05 ± 1.1 | 11 | 11.8 ± 1.2 | 9 | 12 | 0.003 |
CV2 [%] (perforated patch) | 6.7 ± 1.1 | 8 | 6.8 ± 1.2 | 7 | 27 | 0.9 | 3.3 ± 0.4 | 10 | 7.1 ± 1.2 | 9 | 10 | 0.003 |
activity at min. 15 of dopamine [%] (perforated patch) | 43.11 ± 14.3 | 8 | 42.6 ± 12.1 | 8 | 28 | 0.7 | 6.32 ± 3.2 | 13 | 13.66 ± 9.3 | 10 | 97 | 0.9 |
perforated patch/cell-attached in | ||||||||||||
10 mM EGTA (high EGTA, whole-cell) | 10 μM DNIP | 10 μM srDNIP | ||||||||||
juvenile WT | n | juvenile CaV1.3 KO | n | U | p | juvenile CaV1.3 KO | n | juvenile CaV1.3 KO | n | U | p | |
afterhyperpolarisation [mV] (whole-cell) | −56.25 ± 0.7 | 15 | −56.99 ± 0.8 | 19 | 116 | 0.4 | ||||||
pacemaker frequency [Hz] (five minutes) | 1.97 ± 0.2 | 6 | 2.1 ± 0.2 | 7 | 18 | 0.7 | 2.6 ± 0.3 | 11 | 2.49 ± 0.4 | 10 | 50 | 0.7 |
CV ISI [%] | 11.21 ± 1.1 | 6 | 11.31 ± 2 | 7 | 17 | 0.6 | 12.51 ± 1.7 | 8 | 9.12 ± 1.6 | 4 | 10 | 0.3 |
CV2 [%] | 7.05 ± 1 | 6 | 6.27 ± 0.9 | 7 | 16 | 0.5 | 8.06 ± 1.7 | 8 | 7.13 ± 1.9 | 4 | 14 | 0.8 |
activity at min. 15 of dopamine [%] | 65.2 ± 18.1 | 6 | 66.63 ± 13.5 | 7 | 26 | 0.6 | 28.95 ± 11.1 | 6 | 8.43 ± 8.4 | 7 | 7 | 0.03 |